Navigation Links
Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
Date:5/20/2011

rs and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administrati
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
(Date:7/30/2014)... 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... prominent international research and development foundation. ... research-based initiatives, including those addressing health issues. Lightlake ... delivery of naloxone that could widely expand its ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... April 29 Wellcore Corporation, a Silicon Valley-based ... safety, begins shipping its highly anticipated Wellcore system today. ... live more active, independent lives, the Wellcore system offers ... will work outside of the home, unlike other fall ...
... on pharma industry , , , ... two whistleblower lawsuits that is being settled as part of Ortho-McNeil-Janssen Pharmaceuticals Inc.,s and Ortho-McNeil Pharmaceutical LLC,s ... northern Virginia . , , , ... , , ...
Cached Medicine Technology:The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 2The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 2Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 4
(Date:7/30/2014)... is being financially exploited often by their own ... poor and black people. It merits the scrutiny of ... about the dignity and well-being of older Americans, says ... the US. She led one of the largest American ... appear in the Journal of General Internal Medicine ...
(Date:7/30/2014)... A survey of beds within a large teaching hospital in ... with dimensional standards put in place to minimise the risk ... Age and Ageing , therefore emphasises the need for careful ... as well as the need for monitoring and maintenance of ... devices to prevent people falling from bed. However, although the ...
(Date:7/30/2014)... The report entitled “Global Pulse Oximetry Market: ... market dynamics and changing trends in the global pulse ... market sizing of the global pulse oximetry market and ... the same. It further captures the global market share ... market. Further, the report discusses the domestic market of ...
(Date:7/30/2014)... 2014 Los Angeles cosmetic dentist ... treatments that can help patients create their dream smiles ... and gums form the foundation of smile confidence, but ... chips, misshapen teeth or stains may not interfere with ... appearance. The right cosmetic treatments can eliminate chips, erase ...
(Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) ... practice in Westchester County takes the best of everything. ... underlying corporate structure and protocols, and a staff that ... leading Chief Financial Officer to help run it. According ... what it possesses. In fact, in the WCBJ’s July ...
Breaking Medicine News(10 mins):Health News:Older adults are at risk of financial abuse 2Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3
... upright walking of humans? The discovery of four ... (quadrupedality) may help us understand how humans, unlike other primates, ... legs, a scientist will tell the annual conference of the ... The quadrupedal families in Turkey previously attracted attention in 2005, ...
... those with normal version of particular gene respond well ... -- Colon cancer patients who have the normal version ... from a combination treatment that includes adding the targeted ... cancer patients have the normal, or "wild-type" form of ...
... Widely prescribed blood-boosters might stimulate malignant cells, hasten death, ... Drugs used widely to treat anemia in cancer patients ... individuals, but researchers report they may found a way ... may have a test to predict whether a patient ...
... prevent malignancies, study suggests , , SUNDAY, June 1 (HealthDay ... day have value in helping to prevent lung cancer. ... cox-2 inhibitor on the U.S. market, may reduce levels ... The team presented its findings Sunday at the American ...
... CHICAGO, June 1 The combination of two different ... according to a University of Pittsburgh Cancer Institute (UPCI) ... American Society of Clinical Oncology (ASCO) in Chicago. , ... UPCI combined two biotherapies treatments that stimulate the ...
... study says , , SUNDAY, June 1 (HealthDay News) -- People ... are much more likely than other people to develop certain ... a cancer of the lymph nodes, has a cure rate ... future risk of developing second cancers other than HD, according ...
Cached Medicine News:Health News:Genetic mutation linked to walking on all 4s 2Health News:Genetic mutation linked to walking on all 4s 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 2Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
... Kawesch-Lancaster Lasik speculum has wide ... to provide clearance for the ... retract the lids and lashes ... the microkeratome. The blades are ...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Angled 45 degrees....
Medicine Products: